JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Închisă

2.56 20.19

Rezumat

Modificarea prețului

24h

Curent

Minim

2.03

Maxim

2.2

Indicatori cheie

By Trading Economics

Venit

-6.4M

-53M

Vânzări

-9.6M

47M

Marjă de profit

-112.813

Angajați

580

EBITDA

-28M

-49M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+89.55% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

55M

829M

Deschiderea anterioară

-17.63

Închiderea anterioară

2.56

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 aug. 2025, 17:49 UTC

Principalele dinamici ale pieței

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug. 2025, 17:18 UTC

Principalele dinamici ale pieței

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug. 2025, 16:25 UTC

Câștiguri

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug. 2025, 16:42 UTC

Achiziții, Fuziuni, Preluări

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug. 2025, 16:27 UTC

Achiziții, Fuziuni, Preluări

BBVA Says Sabadell Offer Remains in Effect

11 aug. 2025, 16:26 UTC

Achiziții, Fuziuni, Preluări

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Announced TSB Sale on July 1

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparație

Modificare preț

Maravai LifeSciences Holdings Inc (Class A) Așteptări

Obiectiv de preț

By TipRanks

89.55% sus

Prognoză pe 12 luni

Medie 4.17 USD  89.55%

Maxim 7 USD

Minim 2 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMaravai LifeSciences Holdings Inc (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

4

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.02 / 2.115Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.